Dataset Information

From proteomics to discovery of first-in-class ST2 inhibitors active in vivo.

ABSTRACT: Soluble cytokine receptors function as decoy receptors to attenuate cytokine-mediated signaling and modulate downstream cellular responses. Dysregulated overproduction of soluble receptors can be pathological, such as soluble ST2 (sST2), a prognostic biomarker in cardiovascular diseases, ulcerative colitis, and graft-versus-host disease (GVHD). Although intervention using an ST2 antibody improves survival in murine GVHD models, sST2 is a challenging target for drug development because it binds to IL-33 via an extensive interaction interface. Here, we report the discovery of small-molecule ST2 inhibitors through a combination of high-throughput screening and computational analysis. After in vitro and in vivo toxicity assessment, 3 compounds were selected for evaluation in 2 experimental GVHD models. We show that the most effective compound, iST2-1, reduces plasma sST2 levels, alleviates disease symptoms, improves survival, and maintains graft-versus-leukemia activity. Our data suggest that iST2-1 warrants further optimization to develop treatment for inflammatory diseases mediated by sST2.

SUBMITTER: Ramadan AM

PROVIDER: S-EPMC6124397 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

From proteomics to discovery of first-in-class ST2 inhibitors active in vivo.

Ramadan Abdulraouf M AM Daguindau Etienne E Rech Jason C JC Chinnaswamy Krishnapriya K Zhang Jilu J Hura Greg L GL Griesenauer Brad B Bolten Zachary Z Robida Aaron A Larsen Martha M Stuckey Jeanne A JA Yang Chao-Yie CY Paczesny Sophie S

JCI insight 20180726 14

Soluble cytokine receptors function as decoy receptors to attenuate cytokine-mediated signaling and modulate downstream cellular responses. Dysregulated overproduction of soluble receptors can be pathological, such as soluble ST2 (sST2), a prognostic biomarker in cardiovascular diseases, ulcerative colitis, and graft-versus-host disease (GVHD). Although intervention using an ST2 antibody improves survival in murine GVHD models, sST2 is a challenging target for drug development because it binds t ...[more]

PMID: 30046004

Dataset Information

From proteomics to discovery of first-in-class ST2 inhibitors active in vivo.

Publications

From proteomics to discovery of first-in-class ST2 inhibitors active in vivo.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Similar Datasets

Discovery of the First in Vivo Active Inhibitors of the Soluble Epoxide Hydrolase Phosphatase Domain.
| S-EPMC7262789 | biostudies-literature

Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs with in vivo activity in hematological malignancies
2017-08-11 | GSE78932 | GEO

Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors.
| S-EPMC3256935 | biostudies-literature

Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs with in vivo activity in hematological malignancies [array]
2017-08-11 | GSE78517 | GEO

Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs with in vivo activity in hematological malignancies [RNA-Seq]
2017-08-11 | GSE78930 | GEO

Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity.
| S-EPMC8121805 | biostudies-literature

Discovery of the first-in-class potent and isoform-selective human carbonic anhydrase III inhibitors.
| S-EPMC10128460 | biostudies-literature

Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies.
| S-EPMC5458547 | biostudies-literature

Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo.
| S-EPMC4025665 | biostudies-literature

Discovery of a first-in-class EZH2 selective degrader.
| S-EPMC6982609 | biostudies-literature